Your browser doesn't support javascript.
loading
NPS-EQA PART I: Four years' experience in external quality assessment program in Italy for classical and new psychoactive substances analysis in oral fluid.
Marchei, Emilia; Graziano, Silvia; Varì, Maria Rosaria; Minutillo, Adele; Aquilina, Valeria; Pichini, Simona; Rotolo, Maria Concetta.
Afiliação
  • Marchei E; National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.
  • Graziano S; National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.
  • Varì MR; National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.
  • Minutillo A; National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.
  • Aquilina V; Investigation, Crime and International Security, Università degli Studi Internazionali di Roma - UNINT, Rome, Italy.
  • Pichini S; National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy. Electronic address: simona.pichini@iss.it.
  • Rotolo MC; National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.
J Pharm Biomed Anal ; 243: 116084, 2024 Jun 15.
Article em En | MEDLINE | ID: mdl-38452420
ABSTRACT
In 2019, Italian National Institute of Health established an external quality assessment program (EQA) to evaluate the performance of oral fluid testing for classical and new psychoactive substances by laboratories participating in the National Early Warning System collaborative centres. This report presents the results of four rounds between 2019 and 2023. Eleven oral fluid specimens, including 3 blank samples, were prepared by adding different classes of and new psychoactive drugs at known concentrations to pre-screened drug-free oral fluid. False-negative and false-positive results were calculated for the qualitative data evaluation. The quantitative evaluation measured the imprecision and accuracy of the results, in terms of coefficient of variation (CV%) and percent error (ERR%), respectively, with respect to a mean value obtained by reference laboratories. Z-score values were then calculated. Over the years, there has been a significant improvement in false-negative results (from 42.7% in the first year to 19.4% in the last year), but not in false-positive results (from 33.3% in the first year to 22.2% in the last one). In addition to the classic drugs of abuse (e.g. cocaine, amphetamine, methadone), the substances found in false positive samples belonged to the class of synthetic cannabinoids (e.g 5-fluoro CUMYL-PINACA and 5-fluoro-EDMB-PICA), synthetic opioids (e.g butyrylfentanyl) and tryptamines (e.g. 5-methoxy-N-methyl-N-isopropyltryptamine). The four rounds yielded a mean ERR% of approximately 22.1% and a mean CV% of around 41.5%. The participating laboratories demonstrated variable performances in relation to the class of analysed psychoactive substances, as evidenced by the calculated Z-scores. Between 25% and 60% of the reported results in all rounds should be considered satisfactory. EQA is a crucial element of laboratory quality management systems. It promotes continuous improvement and maintains high standards in the field of forensic and clinical drug testing.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canabinoides / Cocaína País/Região como assunto: Europa Idioma: En Revista: J Pharm Biomed Anal Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canabinoides / Cocaína País/Região como assunto: Europa Idioma: En Revista: J Pharm Biomed Anal Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália